ES2603856T3 - Procedimiento para preparar una composición farmacéutica sólida - Google Patents

Procedimiento para preparar una composición farmacéutica sólida Download PDF

Info

Publication number
ES2603856T3
ES2603856T3 ES05730288.7T ES05730288T ES2603856T3 ES 2603856 T3 ES2603856 T3 ES 2603856T3 ES 05730288 T ES05730288 T ES 05730288T ES 2603856 T3 ES2603856 T3 ES 2603856T3
Authority
ES
Spain
Prior art keywords
preparing
pharmaceutical composition
solid pharmaceutical
procedure
perindopril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05730288.7T
Other languages
English (en)
Inventor
Iztok Klobcar
Alesa Puncuh-Kolar
Anica Grandovec
Urska Turk
Polona Solmajer-Lampic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2603856(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE200410019845 external-priority patent/DE102004019845A1/de
Priority claimed from DE102004059521A external-priority patent/DE102004059521A1/de
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2603856T3 publication Critical patent/ES2603856T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento para preparar una composición farmacéutica sólida de perindopril o una sal del mismo, que comprende (i) mezclar en seco perindopril o una sal del mismo con por lo menos un carbonato inorgánico, por lo menos un vehículo y, opcionalmente otros componentes, y (ii) tratar en seco la mezcla obtenida en la etapa (i) hasta la forma sólida deseada.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES05730288.7T 2004-03-29 2005-03-29 Procedimiento para preparar una composición farmacéutica sólida Active ES2603856T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102004019845 2004-03-29
DE200410019845 DE102004019845A1 (de) 2004-03-29 2004-03-29 Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
DE102004059521A DE102004059521A1 (de) 2004-12-09 2004-12-09 Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
DE102004059521 2004-12-09
PCT/EP2005/003277 WO2005094793A1 (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2603856T3 true ES2603856T3 (es) 2017-03-01

Family

ID=34963866

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05730288.7T Active ES2603856T3 (es) 2004-03-29 2005-03-29 Procedimiento para preparar una composición farmacéutica sólida

Country Status (14)

Country Link
US (2) US20070172524A1 (es)
EP (1) EP1729739B1 (es)
JP (1) JP4948392B2 (es)
CY (1) CY1118180T1 (es)
DK (1) DK1729739T3 (es)
EA (1) EA011712B1 (es)
ES (1) ES2603856T3 (es)
HR (1) HRP20161602T1 (es)
HU (1) HUE031058T2 (es)
LT (1) LT1729739T (es)
NO (1) NO20064934L (es)
PL (1) PL1729739T3 (es)
PT (1) PT1729739T (es)
WO (1) WO2005094793A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729739B1 (en) 2004-03-29 2016-09-28 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
SI21800A (sl) * 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
PT1948224E (pt) 2005-11-17 2014-06-12 Silverstone Pharma Est Preparação industrial, e a sua utilização na terapêutica da hipertensão
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
KR20080112387A (ko) * 2006-04-19 2008-12-24 테바 파마슈티컬 인더스트리즈 리미티드 2-아자-비사이클로[3.3.0]-옥탄-3-카르복실산 유도체의 안정한 약학 조성물
CA2652300A1 (en) * 2006-05-15 2007-11-22 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
WO2008068577A2 (en) * 2006-12-01 2008-06-12 Glenmark Pharmaceuticals Limited Pharmaceutical compositions
TWI435917B (zh) 2006-12-27 2014-05-01 Fujifilm Corp 顏料分散組成物、硬化性組成物、彩色濾光片及其製造方法
CA2676437A1 (en) * 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes and their uses
SI22543A (sl) 2007-06-27 2008-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove soli perindoprila
CN102665764A (zh) * 2009-12-22 2012-09-12 Fmc有限公司 可用作可再压实药物赋形剂的微晶纤维素和碳酸钙组合物
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
CN109700774A (zh) * 2019-03-05 2019-05-03 上药东英（江苏）药业有限公司 一种培哚普利叔丁胺片及其粉末直压工艺

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
FR2620699B1 (fr) * 1987-09-17 1990-06-01 Adir Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides
FR2620709B1 (fr) * 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2620703B1 (fr) * 1987-09-17 1991-10-04 Adir Procede de synthese industrielle de l'acide perhydroindole carboxylique - 2(2s, 3as, 7as). application a la synthese de carboxyalkyl dipeptides
US5258525A (en) * 1991-03-27 1993-11-02 Mcneilab, Inc. Processes for preparing [2S-(2α,3aβ,7aβ)]octahydro-1H-indole-2-carboxylic acid and esters
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
FR2771010B1 (fr) * 1997-11-19 2003-08-15 Adir Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires
US6740339B1 (en) 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
FR2807037B1 (fr) * 2000-03-31 2002-05-10 Adir NOUVEAU PROCEDE DE SYNTHESE DES ESTERS DE LA N-[(s)-1- CARBOXYBUTYL]-(S)-ALANINE ET APPLICATION A LA SYNTHESE DU PERINDOPRIL
FR2807431B1 (fr) * 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
FR2807430B1 (fr) * 2000-04-11 2002-05-17 Adir Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811320B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811319B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
DE10038364A1 (de) 2000-08-05 2002-05-02 Hexal Ag Pharmazeutische, Ramipril enthaltende Brauseformulierung
US20020119192A1 (en) 2000-09-22 2002-08-29 Vishwanathan Narayanan Badri Controlled release formulations for oral administration
DE10131217A1 (de) * 2001-06-28 2003-01-09 Solvay Pharm Gmbh 3-Phenyl-3,7-diazabicyclo 3,3,1 nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2357982A1 (en) 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
ATE357933T1 (de) * 2002-01-15 2007-04-15 Actavis Group Hf Formulierungen von quinapril und verwandte ace- hemmer
DE60220877T2 (de) * 2002-01-30 2008-04-10 Les Laboratoires Servier Verfahren zur Herstellung von hochreinem Perindopril und Zwischenverbindungen nützlich in der Synthese
AU2003217916A1 (en) * 2002-03-08 2003-09-22 Teva Pharmeceuticals Usa, Inc. Stable formulations of angiotensin converting enzyme (ace) inhibitors
FR2838648B1 (fr) 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
AU2003241477A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
GB0301471D0 (en) 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
PT1603558E (pt) * 2003-02-28 2008-08-19 Servier S A Lab Processo para a preparação de perindopril e dos seus sais
SI1338591T1 (sl) * 2003-02-28 2006-02-28 Servier Lab NOV POSTOPEK ZA SINTEZO (2S,3aS,7aS)-PERHIDROINDOL-2-KARBOKSILNE KISLINE IN NJENIH ESTROV TER UPORABA PRI SINTEZI PERINDOPRILA
PT1635792E (pt) * 2003-06-26 2009-05-15 Teva Pharma Composições farmacêuticas estáveis de derivados do ácido 2-aza-biciclo[3.3.0]octano-3-carboxílico
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
GB2404336A (en) * 2003-07-30 2005-02-02 Cipla Ltd Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
ES2334900T3 (es) * 2003-09-01 2010-03-17 Les Laboratoires Servier Nuevo procedimiento de sintesis de esteres de n-((s)-1-carboxibutil)-(s)-alanina y su aplicacion a la sintesis de perindopril.
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
EP1729739B1 (en) 2004-03-29 2016-09-28 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
SI21800A (sl) * 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila

Also Published As

Publication number Publication date
CY1118180T1 (el) 2017-06-28
HRP20161602T1 (hr) 2016-12-30
EA011712B1 (ru) 2009-04-28
PT1729739T (pt) 2016-12-01
WO2005094793A1 (en) 2005-10-13
DK1729739T3 (en) 2016-10-31
NO20064934L (no) 2006-10-27
EP1729739B1 (en) 2016-09-28
PL1729739T3 (pl) 2017-04-28
JP4948392B2 (ja) 2012-06-06
US20070172524A1 (en) 2007-07-26
EA200601608A1 (ru) 2007-02-27
US20100172995A1 (en) 2010-07-08
JP2007530623A (ja) 2007-11-01
HUE031058T2 (en) 2017-06-28
LT1729739T (lt) 2016-11-10
EP1729739A1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
ES2603856T3 (es) Procedimiento para preparar una composición farmacéutica sólida
BRPI0607693B8 (pt) processo para produção de um material particulado contendo carbonato de cálcio e opcionalmente vitamina d.
ES2517415T3 (es) Compuesto promotor de la adhesión
ES2477568T3 (es) Uso de uridina en combinación con colina para el tratamiento de trastornos de la memoria
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
BR0300500B1 (pt) composiÇço poliolefÍnica, processo para estabilizaÇço de uma poliolefina e uso de uma mistura.
BR0113001B1 (pt) processo para produzir um absorvente, uma construção absorvìvel e um material absorvìvel.
CL2007003497A1 (es) Producto de cuidado oral que comprende una primera composicion que contiene una sal de calcio insoluble que no es una sal de fosfato de calcio y una segunda composicion que comprende una fuente de iones fosfato; y uso para el blanqueamiento de los di
BRPI0513702A (pt) comprimidos revestidos gelatinosos que se desintegram rapidamente
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
ES2121689B1 (es) Aceleradores para hormigon.
ATE401951T1 (de) Mischer
BRPI0511802A (pt) processo para criação de meios para uso em separadores de ar/óleo
CL2004001426A1 (es) Procedimiento para preparar atorvastatina amorfa que comprende disolver atorvastatina en una solucion que incluye un solvente hidroxilico y evaporar rapidamente dicho solvente desde la solucion; composicion farmaceutica que la contiene, util en el tr
BRPI0607061A2 (pt) aparelho para mistura
DE502004008710D1 (de) Chirurgischer nagel
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
AR058621A1 (es) Metodods para reducir la proteina c reactiva
UY28762A1 (es) Nuevos compuestos
AR052015A1 (es) Agente para la profilaxis o tratamiento del sindrome metabolico
MA51132A (fr) Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci
BR0112120B1 (pt) mistura de copolìmeros enxertados, processo para preparar a mesma, uso de uma mistura de copolìmeros enxertados, e, compósito de múltiplas camadas.